Background To evaluate early urinary (GU) and gastrointestinal (GI) adverse events (AEs)
after two or one fraction of high-dose rate brachytherapy (HDR-BT) in advanced prostate …

Background To evaluate late urinary (GU) and gastrointestinal (GI) adverse events (AEs)
and biochemical control of disease after high-dose rate brachytherapy (HDR-BT) in locally …

PURPOSE: To report the toxicity profile of high-dose-rate (HDR)-brachytherapy (BT) as
monotherapy in a Human Investigation Committee-approved study consisting of a single …

BACKGROUND AND PURPOSE: High-dose-rate brachytherapy (HDR-BT) had been used
only in combination with external beam irradiation (EBI) until our previously reported first trial …

High dose rate (HDR) afterloading brachytherapy in the management of localised prostate
cancer has practical, physical and biological advantages over low dose rate seed …

Purpose To present mature results of high-dose-rate brachytherapy (HDR-BT) as
monotherapy for intermediate-and high-risk prostate cancer. Methods and Materials From …

Background HDR brachytherapy alone is effective for the treatment of localised prostate
cancer when given in 2–4 or more fractions. Single dose treatment has been explored in …

Purpose To present, analyze, and discuss results of a nationwide, multicenter, retrospective
study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate …

Background and purpose High dose-rate (HDR) brachytherapy (BT) provides a highly
conformal method of dose delivery to the prostate. The purpose of this study is to …

Background and purpose To evaluate the oncological outcome of a three-implant high dose
rate (HDR) brachytherapy (BRT) protocol as monotherapy for clinically localised prostate …